Cognition Return On Capital Employed from 2010 to 2024

CGTX Stock  USD 0.40  0.01  2.44%   
Cognition Therapeutics Return On Capital Employed yearly trend continues to be fairly stable with very little volatility. Return On Capital Employed will likely drop to -2.13 in 2024. During the period from 2010 to 2024, Cognition Therapeutics Return On Capital Employed regression line of annual values had significance of  0 and arithmetic mean of (3.83). View All Fundamentals
 
Return On Capital Employed  
First Reported
2010-12-31
Previous Quarter
(2.03)
Current Value
(2.13)
Quarterly Volatility
1.53842211
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 239.4 K, Interest Expense of 25.6 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Latest Cognition Therapeutics' Return On Capital Employed Growth Pattern

Below is the plot of the Return On Capital Employed of Cognition Therapeutics over the last few years. It is Cognition Therapeutics' Return On Capital Employed historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cognition Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Return On Capital Employed10 Years Trend
Slightly volatile
   Return On Capital Employed   
       Timeline  

Cognition Return On Capital Employed Regression Statistics

Arithmetic Mean(3.83)
Coefficient Of Variation(40.16)
Mean Deviation1.28
Median(4.72)
Standard Deviation1.54
Sample Variance2.37
Range4.1644
R-Value0.73
Mean Square Error1.20
R-Squared0.53
Significance0
Slope0.25
Total Sum of Squares33.13

Cognition Return On Capital Employed History

2024 -2.13
2023 -2.03
2022 -1.02
2021 -0.56
2020 -4.5

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' Return On Capital Employed, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Capital Employed(2.03)(2.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.